Moleculin Biotech (MBRX)
(Delayed Data from NSDQ)
$4.32 USD
-0.14 (-3.14%)
Updated Jun 7, 2024 03:59 PM ET
After-Market: $4.32 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth B Momentum D VGM
Brokerage Reports
0 items in cart
Moleculin Biotech, Inc. [MBRX]
Reports for Purchase
Showing records 81 - 100 ( 162 total )
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Annamycin Receives Fast Track in STS-LM, Recently Amended WPD Agreement
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
4Q20: Annamycin Combo AML Trial, Monotherapy in STS-LM, Very Well Funded
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare- Annual ROTH Conference: Cancer Panel Takeaways
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology: Invitation: Virtual 33rd Annual Roth Conference (March 15-17)
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Annamycin Treatment Led to Survival of All Mice in an Osteosarcoma Model
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Enlists Catalyst as CRO for Annamycin Sarcoma/Lung Mets Clinical Program
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Annamycin Cleared by FDA to Begin Trial in Sarcoma Lung Metastases
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
3 Rare Pediatric Disease Designations Potentially Brings 3 Valuable PRVs
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
ASH Abstract Shows Synergy Between Annamycin and Ara-C in AML Mouse Model
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Dr. Reddy Proceeding to Phase 3 in India with 2-DG, Close WP1122 Relative
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
3Q20: Progress Across the Board, Many Shots on Goal
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
3Q20: Progress Across the Board, Many Shots on Goal
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Independent Preclinical Results Support Annamycin''s Targeting to Lung
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J